Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000152

Drug Information
SynonymsApotex Brand of Diflunisal; 3-BIPHENYLCARBOXYLIC ACID, 2',4'-DIFLUORO-4-HYDROXY-; Spectrum3_000392; Reuflos; Nu-Diflunisal; NCGC00016765-02; Diflunisalum; Novopharm Brand of Diflunisal; Dolobid; Frosst SA Brand of Diflunisal; Adomal; SMR000058723; KBio2_001442; CHEBI:39669; CID3059; Merck Sharp & Dohme Brand of Diflunisal; SPECTRUM1500245; [1,1'-Biphenyl]-3-carboxylic acid, 2',4'-difluoro-4-hydroxy-; DivK1c_000938; 2',4'-Difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid; Diflunisal Novopharm Brand; SPBio_002058; 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID; Prestwick3_000039; Prestwick_168; 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid; NCGC00022783-04; 2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid; MK-647; KBioGR_001085; Novo-Diflunisal; Diflunisalum [INN-Latin]; Nu Pharm Brand of Diflunisal; Nu-Pharm Brand of Diflunisal; Diflunisal [USAN:INN:BAN:JAN]; 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid; 5-(2,4-Difluorophenyl)salicylic acid; D3281_SIGMA; CHEMBL898; Dolocid; C01691; AC1L1F2Z; I01-3451; Spectrum4_000513; BSPBio_000137; HMS502O20; UNII-7C546U4DEN; NCGC00022783-03; Spectrum5_000901; Diflunisal (JAN/USP/INN); BIDD:GT0063; KBio2_004010; IDI1_000938; DB00861; EINECS 245-034-9; Flovacil; MK647; CPD000058723; 22494-42-4; Prestwick2_000039; MLS000028678; Spectrum_000962; Dolobil; BSPBio_002203; SBB058143; KBioSS_001442; D004061; HMS1920G10; C13H8F2O3; Dolobid (TN); AB00051969; Merck Brand of Diflunisal; DB06895; Dolisal; SPBio_001163; Algobid; 2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid; HMS1568G19; MK 647; Citidol; HMS2090C16; Prestwick0_000039; BPBio1_000151; KBio2_006578; Dolobis; D00130; Difludol; KBio1_000938; Fluniget; MolPort-001-727-460; Apo-Diflunisal; Unisal; KBio3_001423; MLS001146895; NINDS_000938; 1FL; NCGC00016765-01; diflunisal; 5-[2,4-Difluorophenyl]salicylic acid; Cahill May Roberts Brand of Diflunisal; Fluodonil; HMS2091M20; Spectrum2_001012; Flustar; SAM002554896; Prestwick1_000039; (1,1'-Biphenyl)-3-carboxylic acid, 2',4'-difluoro-4-hydroxy-; LS-44258; Noaldol; BRN 2654431; CAS-22494-42-4; BRD-K22031190-001-05-3; D3281_FLUKA    
Trade NameDolobid    
CompanyMerck & Co    
IndicationPainApproved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAnalgesics    
CAS NumberCAS 22494-42-4
PubChem Compound IDCID 3059.    
PubChem Substance IDSID 4832.    
SuperDrug ATC IDN02BA11;    
SuperDrug CAS ID022494424;    
TargetCyclooxygenase 2Inhibitor[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 073562 To Reference
Ref 2Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc. 2001 Apr;132(4):451-6. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543